TrialNet: University of Florida Clinical Center and Network

$525,802U01FY2017DKNIH

University Of Florida, Gainesville FL

Investigators

Linked publications & trials

Paper 39670998 Paper 39167668 Paper 39137044 Paper 39103721 Paper 38712386 Paper 38621411 Paper 37940642 Paper 37000695 Paper 36920087 Paper 36326757 Paper 36175392 Paper 35998266 Paper 35880956 Paper 35524749 Paper 35041021 Paper 34853027 Paper 34850014 Paper 34642772 Paper 34620616 Paper 34551936 Paper 34127860 Paper 34091488 Paper 33658358 Paper 33496819 Paper 33441381 Paper 33424774 Paper 33277338 Paper 32844178 Paper 32833543 Paper 32747817 Paper 32669415 Paper 32573495 Paper 32502242 Paper 32457058 Paper 32404353 Paper 32248243 Paper 32019856 Paper 32003110 Paper 31982961 Paper 31937610 Paper 31867614 Paper 31794865 Paper 31768570 Paper 31558546 Paper 31180194 Paper 31167877 Paper 30967424 Paper 30894366 Paper 30891858 Paper 30830871 Paper 30830868 Paper 30730939 Paper 30709843 Paper 30629603 Paper 30552130 Paper 30405601 Paper 30275285 Paper 30232284 Paper 30167735 Paper 30089716 Paper 30061316 Paper 30012675 Paper 29931415 Paper 29925930 Paper 29851415 Paper 29769238 Paper 29429978 Paper 29171129 Paper 29164254 Paper 29040630 Paper 29025879 Paper 28956083 Paper 28860125 Paper 28821222 Paper 28770323 Paper 28707353 Paper 28531305 Paper 28520980 Paper 28500393 Paper 28226181 Paper 28202550 Paper 28177779 Paper 28053319 Paper 27980006 Paper 27704166 Paper 27579340 Paper 27456836 Paper 27422577 Paper 27385327 Paper 27362539 Paper 27208341 Paper 27114212 Paper 26991448 Paper 26822082 Paper 26692253 Paper 26375197 Paper 26336066 Paper 26077017 Paper 25689602 Paper 25642774

Abstract

DESCRIPTION (provided by applicant): The University of Florida, a founding member of the DPT-1 and the internationally constituted diabetes trial network (Type 1 Diabetes TrialNet), has made significant and important contributions to TrialNet and type 1 diabetes (T1D), where it participates as one of the top performing Clinical Centers. The primary goal of TrialNet is to prevent and/or delay the development of T1D in persons at risk for the disease by testing interventions targeted at decreasing ?-cell destruction and/or enhancing ?-cell survival. The University of Florida seeks to continue serving as a Clinical Center as part of the TrialNet network. The NIH TrialNet RFA intends to continue providing support for highly productive centers by funding the necessary infrastructure that would enable screening large numbers of T1D relatives so as to identify those at risk of clinical disease. Continuing TrialNet membership would enable our established and highly successful University of Florida Clinical Center and its strong Affiliate network to continue supporting subject recruitment into studies, enhancing trial performance, subject retention, and follow-up. Indeed, our Center is poised to continue the quest for the future prevention and reversal of T1D through its outstanding environment and innovative investigators with proven approaches, each dedicated to identifying a means to prevent/cure the disease as well as to enhance recruitment and retention for T1D clinical trials. In responding to this RFA, this application describes: 1) Unique strengths and contributions of the institution to TrialNet and the T1D field; 2) Ongoing and novel strategies to identify and maintain an active Affiliate network; 3) Recruitment, outreach, and collaboration plans; 4) Strategies to enhancing cost efficiency; 5) Performance monitoring; 6) Consideration of federated IRB; 7) Development of future T1D clinical researchers; and 8) Potential opportunities and challenges for the prevention of T1D currently and over the next 5 years.

View original record on NIH RePORTER →